Subthreshold laser treatment with Endpoint Management in central serous chorioretinopathy

Not Applicable

• Conditions: H35.7; Separation of retinal layers

• Registration Number: DRKS00014299
• Lead Sponsor: Augenklinik der Ludwig-Maximilians Universität München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-05
• Study Completion: 2021-01-01
• Results First Posted: 2021-06-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

Age = 18 years
BCVA better than 0,05
Subject is generally healthy and able to give informed consent.
Diagnosis of CRCS confirmed by retinal specialist
Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant

Exclusion Criteria

Any other macular disease with possibility of developing subretinal fluid: vitreomacular traction syndrome, epiretinal membranes, age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, uveitis
Ocular surgery for 6 months preceding the study
Previous intravitreal injections of anti-VEGF, steroids within 6 months preceding the study
Previous macular laser treatment or photodynamic therapy within 3 months preceding the study
Present ocular infection or clinically significant inflammation
Patient is not able to cooperate or has any other medical or psychological condition that prohibits him from regular follow-up
Kidney failure or dialysis
Allergy to fluorescein
Participation in a clinical trial in the 30 days preceding the study
Planned intraocular surgery within one 12 months
Women: Pregnancy or currently breast-feeding
History of systemic or topical corticosteroid use within last 6 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Average reduction of central retinal thickness as measured by spectral domain optical coherence tomography (SD OCT) after 6 months

Secondary Outcome Measures

Name	Time	Method
Change in Visual acuity (Early Treatment of Diabetic Retinopathy Study- charts, best corrected visual acuity), Macular function (MAIA® microperimetry) and central choroidal thickness (spectraldomain optical coherence tomography) after 6 and 12 months. Rate of total subretinal fluid resorption and recurrence rate after 6 and 12 months.